Cyto-Facto Signs Letter of Intent with Steminent for Contract Manufacturing of Stemchymal

Cyto-Facto Inc. (Headquarters: Kobe, Hyogo, Japan; President & CEO: Yasunori Ishibashi; “Cyto-Facto”) announces that it has entered into a Letter of Intent (“LOI”) with Steminent Biotherapeutics Inc. (Headquarters: Taipei, Taiwan; Chairman & CEO: Ling-Mei Wang; “Steminent”) regarding the contract manufacturing of Steminent’s Mesenchymal stem cell product, Stemchymal.

Healios Announces the Submission of Clinical Trial Notification in Japan for the Global Phase 3 REVIVE-ARDS Study

HEALIOS K.K. announces that they have submitted a clinical trial plan notification to the Pharmaceuticals and Medical Devices Agency (PMDA) for a clinical trial to be conducted in Japan as part of the Global Phase 3 trial (REVIVE-ARDS) for HLCM051 (invimestrocel) for the treatment of ARDS (Acute Respiratory Distress Syndrome). Following a 14-day review period after submitting the clinical trial plan notification to PMDA, they plan to commence this trial.

Healios Initiates Production of Culture Supernatant at In-house Cell Processing Facility

HEALIOS K.K. is advancing research and development aimed at utilizing the technology they possess for producing regenerative medicine products and the culture supernatant generated during their production process. To prepare for the anticipated full-scale production of culture supernatant, they have been developing a Cell Processing Center (CPC) within the Business Support Center for Biomedical Research Activities (BMA) in Kobe. They are pleased to announce that this facility has now commenced full operations.
Culture supernatant holds promise for utilization across various fields, including as a material for pharmaceuticals and cosmetics. Healios is advancing discussions with multiple reputable business partners regarding research and sales aimed at utilizing culture supernatant. They will leverage this CPC for these applications.

Healios - Announcement of Letter of Intent with Alfresa Corporation regarding the Sale and Purchase of Somatic Stem Cell Culture Supernatant

HEALIOS K.K. announces that they have submitted a clinical trial plan notification to the Pharmaceuticals and Medical Devices Agency (PMDA) for a clinical trial to be conducted in Japan as part of the Global Phase 3 trial (REVIVE-ARDS) for HLCM051 (invimestrocel) for the treatment of ARDS (Acute Respiratory Distress Syndrome). Following a 14-day review period after submitting the clinical trial plan notification to PMDA, they plan to commence this trial.